Study of Daclizumab in Patients With Chronic, Persistent Asthma

Completed · Phase 2

Conditions studied: Asthma

In brief

The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.

Key facts

Study ID
NCT00028288
Run by
Facet Biotech
People needed
120
Starts
2001-09-01
Expected to finish
2003-12-01
Last updated by the study team
2012-03-13

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.